Eikonoklastes Therapeutics raised $13.56 million to develop immunotherapies for rare and aggressive solid tumors, including triple-negative breast cancer, ovarian cancer, and metastatic melanoma.
Eikonoklastes Therapeutics raised $13.56 million to develop immunotherapies for rare and aggressive solid tumors, including triple-negative breast cancer, ovarian cancer, and metastatic melanoma.
